HIV Mutation Detail Information

> E138T Search Result


Mutation Information
Mutation Site E138T
Mutation Type Amino acid level
Gene/Protein/Region Type IN
Relevant Drug dolutegravir (DTG)
Literature Information
PubMed PMID 27539455
Published Year 2016
Journal Infectious diseases and therapy
Title New Antiretroviral Treatment for HIV.
Author Badowski ME,Pérez SE,Biagi M,Littler JA
Evidence The efficacy of dolutegravir twice daily is reduced in the presence of INSTI-resistance Q148 substitution along with two or more additional INSTI-resistance substitutions including T66A, L74I/M, E138A/K/T, G140S/A/C, Y143R/C/H, E157Q, G163S/E/K/Q, or G193E/R.

Contents
Description
Mutation Information Note
  • Gene/Protein/Region Type: Virus Gene (e.g. LMP-1) or Virus Protein (e.g. Rep 68) or Virus Region (e.g. S, X)
Literature Information Note
  • Evidence: sentence contains this mutation information in the citation